Monitoring data conducted by the Italian Medicines Agency (AIFA) on oral antiviral drugs for the treatment of COVID-19 during the pandemic have been analyzed in a study just published in the scientific journal The Lancet Regional Health - Europe. The publication was received with much interest by the scientific community both for the robustness and volume of data collected through the AIFA Monitoring Registries and for the statistical methodology applied in interpreting the results. Rigorous investigations conducted on robust data acquired in real life are indeed able to provide valuable clinical evidence on the efficacy and safety of therapies that have obtained authorization for emergency use, following favorable results from randomized clinical trials. Indeed, in the editorial accompanying publication in the journal, the authors highlight that the study "marks an important step toward an evidence-based approach to the treatment of COVID-19 in high-risk patients" and "provides detailed information on treatment efficacy that may pave the way for a more personalized approach to future therapeutic strategies".
|